Pyrazole trk kinase inhibitors for the treatment of cancer

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 3, 2007, Pages 351-356

  Hudkins, Robert L ^a   Josef, Kurt A ^a  

^a CEPHALON INC   (United States)

Author keywords

NGF; Pyrazole; TrkA

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINO ACID DERIVATIVE; ANTINEOPLASTIC AGENT; CEP 2563; CEP 3555; CEP 701; CEP 751; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; ISOTHIAZOLE DERIVATIVE; OXINDOLE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; DRUG DESIGN; DRUG INDUSTRY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; STRUCTURE ANALYSIS;

EID: 33847743421     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.3.351     Document Type: Article

References (33)

1. GLASS DJ, YANCOPOULOS GD: The neurotrophins and their receptors. Trends Cell Biol. (1993) 3:262-268.
2. PATAPOUTIAN A, REICHARDT LF: Trk receptors: mediators of neurotrophin action. Curr. Opin. Neurobiol. (2001) 11:272-280.
3. MEAKIN SO, SHOOTER EM: The nerve growth factor family of receptors. Trends Neurosci. (1992) 15:323-331.
4. ULLRICH A, SCHLESSINGER J: Signal transduction by receptor with tyrosine kinase activity. Cell (1990) 61:203-212.
5. KAPLAN DR, HEMPSTEAD BL, MARTIN-ZANCA D, CHAO MV, PARADA LF: The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science (1991) 252:554-558.
6. KAPLAN DR, STEPHENS MR: Neurotrophin signal transduction by the trk receptor. J. Neurobiol. (1994) 25:1404-1417.
7. THOENEN H, BARDE YA: Physiology of nerve growth factor. Physiol. Rev. (1980) 60:1284-1335.
8. DISTEFANO PS: Pharmacology of neurotrophic factors in models of neurodegenerative diseases. Annu. Rep. Med. Chem. (1993)28:11-17.
9. RUGGERI BA, MIKNYOCZKI SJ, SINGH J, HUDKINS RL: Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective rrk tyrosine kinase inhibitors in pre-clinical tumor models. Curr. Med. Chem. (1999) 6:845-857.
10. MIKNYOCZKI SJ, KLEIN-SZANTO AJ, RUGGERI BA: Neurotrophin-trk receptor interactions in neoplasia: a possible role in interstitial and perineural invasion in ductal pancreatic cancer. Crit. Rev. Oncogen. (1996) 7:89-100.
11. MIKNYOCZKI SJ, LANG L, KLEIN-SZANTO AJ, DIONNE CA, RUGGERI BA: Neurotrophins and trk receptors in human pancreatic ductal adrenocarcinoma: expression patterns and effects on in vitro invasive behavior. Int. J. Cancer (1999) 81:417-427.
12. MIKNYOCZKI SJ, WAN W, CHANG H et al.: The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenographs in nude mice. Clin. Cancer Res. (2002) 8:1924-1931.
13. PFLUG BR, DIONNE CA, KAPLAN DR, LYNCH J, DJAKIEW D: Expression of a high affinity nerve growth factor receptor in the human prostate. Endocrinology (1995) 136:262-268.
14. WEERARATNA AT, ARNOLD JT, GEORGE DJ, DEMARZO A, ISAACS JT: Rational basis for trk inhibition therapy for prostate cancer. Prostate (2000) 45:140-148.
15. TAGLIABUE E, CASTIGLIONI F, GHIRELLI C et al.: Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells. J. Biol. Chem. (2000) 275:5388-5394.
16. TOGNON C, KNEZEVICH SR, HUNTSMAN D et al.: Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell (2002) 2:367-376.
17. DAVIDSON B, REICH R, LAZAROVICI P: Expression and activation of the nerve growth factor receptor trkA in serous ovarian carcinoma. Clin. Cancer Res. (2003) 9:2248-2259.
18. BARDELLI, A, PARSONS DW, SILLIMAN N et al.: Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 300:949.
19. GRECO A, ROCCATO E, PIEROTTI MA: Trk oncogenes in papillary thyroid carcinoma. Cancer Treatment Res. (2004) 122:207-219
20. MENTER DG, HERRMANN JL, NICOLSON GL: The role of trophic factors and autocrine/paracrine growth factors in brain marastasis. Clin. Exp. Metastasis (1995) 13:67-88.
21. NICOLSON GL, MENTERDG, HERRMANN JL et al.: Tumor metastasis to brain: role of endothelial cells, neurotrophins and paracrine growth factors. Crit. Rev. Oncol. (1994) 5:451-471.
22. DJAKIEW D, DELSITE R, PFLUG B et al.: Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res. (1991) 51:3304.
23. WEERARATNA AT, DALRYMPLE SL, LAMB JC: Pan-trk inhibition decreases metastasis and enhances host survival in experimental models due to its selective induction of apoptosis of prostate cancer cell. Clin. Cancer Res. (2001)7:2237-2245.
24. ANGELES TS, STEFFLER C, HUDKINS RL et al.: Enzyme-linked immunosorbent assay for trkA tyrosine kinase activity. Anal. Biochem. (1996) 206:49-55.
25. HUDKINS RL, IQBAL M, PARK CH et al.: Prodrug esters of the indolocarbazole CEP-751. Bioorg. Med. Chem. Lett. (1998) 8:1873-1876.
26. DIONNE C, CAMORATTO A, JANI J et al.: Cell cycle independent-death of prostate adenocarcinoma is induced by trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin. Cancer Res. (1998) 4:1887-1898.
27. CAMORATTO AM, JANI J, ANGELES TS et al.: CEP-751 inhibits trk receptor tyrosine kinase activity in vitro and exhibits anti-tumor activity. Int. J. Cancer (1997) 72:673-679.
28. UNDEVIA SD, VOGELZANG NJ MAUER AM, JANISCH L, MANI S, RATAIN MJ: Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest. New Drugs (2004) 22:449-458.
29. MARSHALL JL, KINDLER H, DEEKEN J: Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest. New Drugs (2005) 23:31-7.
30. MIKNYOCZKI SJ, CHANG H, KLEIN-SZANTO AJ, DIONNE CA, RUGGERI BA: The trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin. Cancer Res. (1999) 5:2205-2212.
31. GEORGE DJ, DIONNE CA, JANI J et al.: Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and trk tyrosine kinase inhibitors. CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res. (1999) 59:2395-2401.
32. GINGRICH DL, ANGELES TS, HUDKINS RL et al.: Synthesis, modeling and in vitro activity of 3′-(S)-epi-K-252a analogs. Elucidating the stereochemical requirements of the 3′-sugar alcohol on trkA tyrosine kinase activity. J. Med. Chem. (2005) 48:3776-3783.
33. GINGRICH DL, HUDKINS RL: Synthesis and kinase inhibitory activity of Med. Chem. Lett. 3′-(S)-epi-K-252a. Bioorg. (2002) 12:2829-2831.